<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1505">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01929200</url>
  </required_header>
  <id_info>
    <org_study_id>BD-IC-IV50</org_study_id>
    <nct_id>NCT01929200</nct_id>
  </id_info>
  <brief_title>Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation</brief_title>
  <official_title>Randomized, Open-label, Multicenter Study of Icotinib as Adjuvant Therapy in Treating Stage II-IIIA Non-small-cell Lung Cancer Patients With Positive EGFR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Betta Pharmaceuticals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Betta Pharmaceuticals Co.,Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adjuvant therapy has been proved effective in treating stage II-IIIA non-small-cell lung
      cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in
      treating such patients. The primary endpoint is to compare the recurrence-free survival
      after 1-year or 2-year treatment with icotinib.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recurrence-free Survival</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1-year treatment with icotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 1-year treatment with icotinib after operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-year treatment with icotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 2-year treatment with icotinib after operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1-year treatment with icotinib</intervention_name>
    <description>Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.</description>
    <arm_group_label>1-year treatment with icotinib</arm_group_label>
    <other_name>Commana</other_name>
    <other_name>BPI-2009</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-year treatment with icotinib</intervention_name>
    <description>Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.</description>
    <arm_group_label>2-year treatment with icotinib</arm_group_label>
    <other_name>Commana</other_name>
    <other_name>BPI-2009</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients signed the written informed consent

          -  The patients present with operable stage II-IIIA non-small-cell lung cancers with 19
             or 21 exon mutation

          -  The patients have no history of anti-cancer therapies including chemotherapy,
             radiation therapy

          -  The patients' Eastern Cooperative Oncology Group scores are â‰¤ 0-2

        Exclusion Criteria:

          -  Patients with unresected tumor

          -  Wild EGFR type

          -  Allergic to the study drug

          -  Patients have severe non-cancerous diseases

          -  Patients are undergoing current administration of anti-cancer therapies, or are
             attending some other clinical trials
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yue Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yue Yang, MD</last_name>
    <phone>86-10-88196568</phone>
    <email>zlyangyue@bjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Yang, MD</last_name>
      <phone>86-10-88196568</phone>
      <email>zlyangyue@bjmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yue Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lv C, Ma Y, Feng Q, Fang F, Bai H, Zhao B, Yan S, Wu N, Zheng Q, Li S, Chen J, Wang J, Feng Y, Wang Y, Pei Y, Fang J, Yang Y. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma. World J Surg Oncol. 2013 Apr 26;11:96. doi: 10.1186/1477-7819-11-96.</citation>
    <PMID>23621919</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>August 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
